Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



**In the claims**

a'

1. (amended) A compound of Formula I:




wherein

$R^1$, $R^2$, $R^3$ and $R^4$ are independently

H,

HO,

$R^{13}O$-,

Halogen[ (F, Cl, Br)],

C1-C3-alkyl,

$CF_3$,

$R^{14}CO_2$-,

$R^{14}O_2C$-,

$R^{14}CO$-,

$R^{14}CONH$-,

$R^{14}NHCO$-,

$R^{14}NHCO_2$-,

$R^{14}OCONH$-,





MAR. 20. 2003 1:58PM HOLLAND & KNIGHT NO. 3533 P. 8

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



$R^{14}O_2S$-,

$R^{14}OS$-,

a'

$R^{14}S$-, or

$R^{15}R^{16}N$-; or

$R^1$ and $R^2$, or $R^2$ and $R^3$, or $R^3$ and $R^4$ taken together can be

$-SCH_2S$-,

$-SCH_2O$-,

$-OCH_2S$-,

$-SCH_2CH_2S$-,

$-SCH_2CH_2O$-, or

$-OCH_2CH_2S$-;

wherein one of $R^1$, $R^2$, $R^3$ and $R^4$ must be C1-C3-alkoxy or C1-C3-alkylthio group;

$R^5$, $R^6$, $R^7$, and $R^8$ are independently

H,

C1-C6-alkyl,

C3-C6-alkenyl,

C3-C6-cycloalkyl,

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen[ (F, Cl, Br)], $R^{13}O$-, $CF_3$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}CO$, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CONH$-, $R^{14}NHCO$; or

$R^5$ and $R^6$ taken together can be C3-C6-cycloalkyl;

$R^7$ and $R^8$ taken together can be C3-C6-cycloalkyl;



MAR. 20. 2003 1:58PM HOLLAND & KNIGHT NO. 3533 P. 9

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



$R^9$ is

$R^{15}R^{16}NCO$-,

$R^{15}R^{16}NCS$-,

$R^{15}R^{16}N(CR^{17})$-,

$R^{17}OCO$-,

$R^{15}CO$-,

$R^{15}R^{16}NCH_2CO$-,

$R^{14}O_2C$-$(CH_2)_n$-,

$R^{15}R^{16}NCO$-$(CH_2)_n$-,

NC-$(CH_2)_n$-,

H,

C1-C6-alkyl,

C3-C6-alkenyl, or

C3-C6-cycloalkyl; or

$R^8$ and $R^9$ taken together can be

–$(CH_2)_mCH_2(R^{15})NCO$-,

–$(CH_2)_mCH_2OCO$-, or

–$(CH_2)_mCH_2CH_2CO$-;

$R^{10}$ and $R^{11}$ are independently

H,

$R^{15}R^{16}N$-,

$R^{15}R^{16}N(CR^{17})$-,



MAR. 20. 2003 1:58PM HOLLAND & KNIGHT NO. 3533 P. 10

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



$R^{14}HNCO$-, or

$R^{14}CONH$-;

a'

$R^{12}$ is

H,

Halogen[ (F, Cl, Br)],

HO,

$R^{13}O$-,

$R^{15}R^{16}N$-,

C1-C3-alkyl,

$CF_3$,

$R^{14}CO_2$-,

$R^{14}CO$-, or

$R^{14}CONH$-;

$R^{13}$ is C1-C3-alkyl;

$R^{14}$ is H or C1-C3-alkyl;

$R^{15}$ and $R^{16}$ are independently

H,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10-alkenyl, or

C3-C6-cycloalkyl; or

$R^{15}$ and $R^{16}$ taken together can be C3-C6-cycloalkyl;



MAR. 20. 2003 1:59PM HOLLAND & KNIGHT NO. 3533 P. 11

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



$R^{17}$ is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl;

n is 1 to 6;

m is 0 to 2;

and pharmaceutically acceptable salts thereof;

wherein $R^{10}$ and $R^{11}$ cannot be both H.

2. (amended) The compound of claim 1 of Formula I wherein

one of four substituents of $R^1$, $R^2$, $R^3$ and $R^4$ must be C1-C3-alkylthio group or C1-C3-alkoxy group, the other substituents are independently H, $R^{13}O$-, [$R^{13}S$-] $\underline{R^{14}S}$-, halogen[ (F, Cl, Br)], or C1-C3-alkyl;

$R^2$ and $R^3$ taken together can be $-SCH_2S$-, $-SCH_2O$-, or $-OCH_2S$-;

$R^9$ is

$R^{15}R^{16}NCO$-,

$R^{15}R^{16}NCS$-,

$R^{15}R^{16}N(CR^{17})$-,

$R^{17}OCO$-, or

$R^{15}CO$-[, or]

H;

$R^{10}$ and $R^{11}$ are independently H, $H_2N$-, or $CH_3CONH$-; and pharmaceutically acceptable salts thereof.

3. (amended) A composition comprising [The]the compound of claim 2 and [further comprising] a pharmaceutically acceptable carrier.





MAR. 20. 2003 1:59PM HOLLAND & KNIGHT NO. 3533 P. 12

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



4. (amended) The [compound] composition of claim 3 in a dosage form comprising a therapeutically effective amount of the compound for treating a disorder in a patient associated with excessive activation of the α-amino-3-hydroxy-5-methyl-4-isooxazoleproprionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors.

a'

5. (amended) The compound of claim 2 of Formula I selected from the group consisting of

1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5*H*-2,3-benzodiazepine, [1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine,] 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methoxy-5*H*-2,3-



MAR. 20. 2003 1:59PM HOLLAND & KNIGHT NO. 3533 P. 13

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



a'

benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-acetyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-



MAR. 20. 2003 1:59PM HOLLAND & KNIGHT NO. 3533 P. 14

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



propylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-acetyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, and 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine.

a'

6. (amended) A composition comprising [The] the compound of claim 5 [further comprising] and a pharmaceutically acceptable carrier.

7. (amended) The [compound] composition of claim 6 in a dosage form comprising a therapeutically effective amount of the compound for treating a disorder in a patient associated with excessive activation of the α-amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors.

8. (amended) A composition comprising the [The] compound of claim 1 [further comprising] and a pharmaceutically acceptable carrier.

9. (amended) The [compound] composition of claim 8 in a dosage form comprising a therapeutically effective amount of the compound for treating a disorder in a patient associated with excessive activation of the α-amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors.

10. (amended) A method for treating a patient having a disorder associated with excessive activation of the α-amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA)



MAR. 20. 2003 1:59PM HOLLAND & KNIGHT NO. 3533 P. 15

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



subtype of the ionotropic excitatory amino acid (EAA) receptors, the method comprising administering to the patient, in an effective amount to alleviate the symptoms of the disorder, a compound of Formula I:

Q'



wherein

$R^1$, $R^2$, $R^3$ and $R^4$ are independently

H,

HO,

$R^{13}O$-,

halogen[(F, Cl, Br)],

C1-C3-alkyl,

$CF_3$,

$R^{14}CO_2$-,

$R^{14}O_2C$-,

$R^{14}CO$-,

$R^{14}CONH$-,

$R^{14}NHCO$-,

$R^{14}NHCO_2$-,



MAR. 20. 2003 2:00PM HOLLAND & KNIGHT NO. 3533 P. 16

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



$R^{14}OCONH$-,

$R^{14}O_2S$-,

$R^{14}OS$-,

$R^{14}S$-, or

$R^{15}R^{16}N$-; or

$R^1$ and $R^2$, or $R^2$ and $R^3$, or $R^3$ and $R^4$ taken together can be

$-SCH_2S$-,

$-SCH_2O$-,

$-OCH_2S$-,

$-SCH_2CH_2S$-,

$-SCH_2CH_2O$-, or

$-OCH_2CH_2S$-;

wherein one of $R^1$, $R^2$, $R^3$ and $R^4$ must be C1-C3-alkoxy or C1-C3-alkylthio group;

$R^5$, $R^6$, $R^7$, and $R^8$ are independently

H,

C1-C6-alkyl,

C3-C6-alkenyl,

C3-C6-cycloalkyl,

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen[ (F, Cl, Br)], $R^{13}O$-, $CF_3$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}CO$, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CONH$-, $R^{14}NHCO$; or

$R^5$ and $R^6$ taken together can be C3-C6-cycloalkyl;



MAR. 20. 2003 2:00PM HOLLAND & KNIGHT NO. 3533 P. 17

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



$R^7$ and $R^8$ taken together can be C3-C6-cycloalkyl;

$R^9$ is

$R^{15}R^{16}NCO$-,

$R^{15}R^{16}NCS$-,

$R^{15}R^{16}N(CR^{17})$-,

$R^{17}OCO$-,

$R^{15}CO$-,

$R^{15}R^{16}NCH_2CO$-,

$R^{14}O_2C$-$(CH_2)_n$-,

$R^{15}R^{16}NCO$-$(CH_2)_n$-,

NC-$(CH_2)_n$-,

H,

C1-C6-alkyl,

C3-C6-alkenyl, or

C3-C6-cycloalkyl; or

$R^8$ and $R^9$ taken together can be

–$(CH_2)_m CH_2(R^{15})NCO$-,

–$(CH_2)_m CH_2OCO$-, or

–$(CH_2)_m CH_2CH_2CO$–;

$R^{10}$ and $R^{11}$ are independently

H,

$R^{15}R^{16}N$-,





MAR. 20. 2003 2:00PM HOLLAND & KNIGHT NO. 3533 P. 18

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



$R^{15}R^{16}N(CR^{17})$-,

$R^{14}HNCO$-, or

$R^{14}CONH$-;

a'

$R^{12}$ is

H,

Halogen[ (F, Cl, Br)],

HO,

$R^{13}O$-,

$R^{15}R^{16}N$-,

C1-C3-alkyl,

$CF_3$,

$R^{14}CO_2$-,

$R^{14}CO$-, or

$R^{14}CONH$-;

$R^{13}$ is C1-C3-alkyl;

$R^{14}$ is H or C1-C3-alkyl;

$R^{15}$ and $R^{16}$ are independently

H,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10-alkenyl, or

C3-C6-cycloalkyl; or



MAR. 20. 2003 2:00PM HOLLAND & KNIGHT NO. 3533 P. 19

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



$R^{15}$ and $R^{16}$ taken together can be C3-C6-cycloalkyl;

$R^{17}$ is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl;

a'

n is 1 to 6;

m is 0 to 2;

and pharmaceutically acceptable salts thereof;

wherein $R^{10}$ and $R^{11}$ cannot be both H,

in combination with a pharmaceutically acceptable carrier.

11. (amended) The method of claim 10 wherein, in the compound of Formula I, one of four substituents of $R^1$, $R^2$, $R^3$ and $R^4$ must be C1-C3-alkylthio group or C1-C3-alkoxy group, the other substituents are independently H, $R^{13}O$-, [$R^{13}S$-] $\underline{R^{14}S}$-, halogen[ (F, Cl, Br)], or C1-C3-alkyl;

$R^2$ and $R^3$ taken together can be $-SCH_2S$-, $-SCH_2O$-, or $-OCH_2S$-;

$R^9$ is

$R^{15}R^{16}NCO$-,

$R^{15}R^{16}NCS$-,

$R^{15}R^{16}N(CR^{17})$-,

$R^{17}OCO$-, or

$R^{15}CO$-[, or]

H;

$R^{10}$ and $R^{11}$ are independently H, $H_2N$-, or $CH_3CONH$-; and pharmaceutically acceptable salts thereof.



MAR. 20. 2003 2:00PM HOLLAND & KNIGHT NO. 3533 P. 20

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



13. (amended) The method of claim 11 wherein the compound of Formula I is selected from the group consisting of

a2

1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5*H*-2,3-benzodiazepine, [1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine,] 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-



MAR. 20. 2003 2:00PM HOLLAND & KNIGHT NO. 3533 P. 21

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



$a^2$

ethylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-acetyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-acetyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-





MAR. 20. 2003 2:01PM HOLLAND & KNIGHT NO. 3533 P. 22

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, and 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine.

16. (amended) A compound of Formula II:




wherein

$R^1$[, $R^2$, $R^3$] and $R^4$ are independently

H,

HO,

$R^{13}O$-,

Halogen[ (F, Cl, Br)],

C1-C3-alkyl,

$CF_3$,

$R^{14}CO_2$-,

$R^{14}O_2C$-,

$R^{14}CO$-,

$R^{14}CONH$-,





MAR. 20. 2003 2:01PM HOLLAND & KNIGHT NO. 3533 P. 23

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



$R^{14}NHCO$-,

$R^{14}NHCO_2$-,

$R^{14}OCONH$-,

$R^{14}O_2S$-,

$R^{14}OS$-,

$R^{14}S$-, or

$R^{15}R^{16}N$-; or

$R^2$ is one of H, HO, $R^{13}O$-, halogen, C1-C3-alkyl, $CF_3$, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}S$- and $R^{15}R^{16}N$- when $R^3$ is one of HO, halogen, C1-C3-alkyl, $CF_3$, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}S$-, and $R^{15}R^{16}N$-; or

$R^2$ is one of H, HO, halogen, C1-C3-alkyl, $CF_3$, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}S$- and $R^{15}R^{16}N$- when $R^3$ is one of H, HO, $R^{13}O$-, halogen, C1-C3-alkyl, $CF_3$, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}S$-, and $R^{15}R^{16}N$-; or

$R^1$ and $R^2$, or $R^2$ and $R^3$, or $R^3$ and $R^4$ taken together can be

$-SCH_2S$-,

$-SCH_2O$-,

$-OCH_2S$-,

$-SCH_2CH_2S$-,

$-SCH_2CH_2O$-, or

$-OCH_2CH_2S$-; or



MAR. 20. 2003 2:01PM HOLLAND & KNIGHT NO. 3533 P. 24

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



one of four substituents of $R^1$, $R^2$, $R^3$ and $R^4$ must be C1-C3-alkoxy or C1-C3-alkylthio group;

$R^5$, $R^6$, and $R^7$ are independently

H,

C1-C6-alkyl,

C3-C6-alkenyl,

C3-C6-cycloalkyl, or

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen[ (F, Cl, Br)], $R^{13}O$-, $CF_3$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}CO$, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CONH$-, $R^{14}NHCO$; or

$R^5$ and $R^6$ taken together can be C3-C6-cycloalkyl;

$R^{13}$ is C1-C3-alkyl;

$R^{14}$ is H or C1-C3-alkyl;

$R^{15}$ and $R^{16}$ are independently

H,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10-alkenyl, or

C3-C6-cycloalkyl; or

$R^{15}$ and $R^{16}$ taken together can be C3-C6-cycloalkyl;

[$R^{17}$ is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl;]

$R^{18}$ and $R^{19}$ are independently





MAR. 20. 2003 2:01PM HOLLAND & KNIGHT NO. 3533 P. 25

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



H,

Halogen[ (F, Cl, Br)],

C1-C3-alkyl,

$R^{14}O$-,

$CF_3$-, or

$R^{14}CO_2$-;

$R^{20}$ and $R^{21}$ are independently

H,

$R^{15}R^{16}N$-,

$R^{15}HNC(NH)$-, or

$R^{14}CONH$-;

and pharmaceutically acceptable salts thereof;

wherein $R^{20}$ and $R^{21}$ cannot both be H.

17. (amended) The compound of claim 16 of Formula II wherein one of four substituents of $R^1$, $R^2$, $R^3$ and $R^4$ must be C1-C3-alkylthio or C1-C3-alkoxy group, the other substituents are independently H, $R^{13}O$-, $R^{13}S$-, halogen[ (F, Cl, Br)], or C1-C3-alkyl; $R^2$ and $R^3$ taken together can be $-SCH_2S$-, $-SCH_2O$-, or $-OCH_2S$-; $R^{20}$ and $R^{21}$ are independently H, $H_2N$-, or $CH_3CONH$-; and pharmaceutically acceptable salts thereof.

18. (amended) A composition comprising the [The] compound of claim 17 [further comprising] and a pharmaceutically acceptable carrier.



MAR. 20. 2003 2:01PM HOLLAND & KNIGHT NO. 3533 P. 26

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



19. (amended) The composition [compound] of claim 18 in a dosage form comprising a therapeutically effective amount of the compound for treating a disorder in a patient associated with excessive activation of the α-amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors.

a3

20. (amended) The compound of claim 17 of Formula II selected from the group consisting of

1-(4-Aminophenyl)-4-methyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-4-methyl-7-methoxy-5*H*-2,3-benzodiazepine, [1-(4-Aminophenyl)-4-methyl-8-methoxy-5*H*-2,3-benzodiazepine,] 1-(4-Aminophenyl)-7-amino-4-methyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-4-methyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-4-methyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-4-methyl-8-methylthio-5*H*-2,3-benzodiazepine, and 1-(4-Aminophenyl)-7-amino-4-methyl-8-methylthio-5*H*-2,3-benzodiazepine.

21. (amended) A composition comprising the compound of claim 20 [further comprising] and a pharmaceutically acceptable carrier.

22. (amended) The composition [compound] of claim 21 in a dosage form comprising a therapeutically effective amount of the compound for treating a disorder in a patient associated with excessive activation of the α-amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors.

23. (amended) A composition comprising the [The] compound of claim 16 [further comprising] and a pharmaceutically acceptable carrier.



MAR. 20. 2003 2:02PM HOLLAND & KNIGHT NO. 3533 P. 27

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



24. (amended) The composition [compound] of claim 23 in a dosage form comprising a therapeutically effective amount of the compound for treating a disorder in a patient associated with excessive activation of the α-amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors.

a3

25. (amended) A method for treating a patient having a disorder associated with excessive activation of the α-amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors, the method comprising administering to the patient, in an effective amount to alleviate the symptoms of the disorder, a compound of Formula II:




wherein

$R^1$[, $R^2$, $R^3$] and $R^4$ are independently

H,

HO,

$R^{13}O$-,

Halogen[ (F, Cl, Br)],

C1-C3-alkyl,

$CF_3$,



MAR. 20. 2003 2:02PM HOLLAND & KNIGHT NO. 3533 P. 28

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



$R^{14}CO_2$-,

$R^{14}O_2C$-,

$R^{14}CO$-,

$R^{14}CONH$-,

$R^{14}NHCO$-,

$R^{14}NHCO_2$-,

$R^{14}OCONH$-,

$R^{14}O_2S$-,

$R^{14}OS$-,

$R^{14}S$-, or

$R^{15}R^{16}N$-; or

$R^2$ is one of H, HO, $R^{13}O$-, halogen, C1-C3-alkyl, $CF_3$, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}S$- and $R^{15}R^{16}N$- when $R^3$ is one of HO, halogen, C1-C3-alkyl, $CF_3$, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}S$-, and $R^{15}R^{16}N$-; or

$R^2$ is one of H, HO, halogen, C1-C3-alkyl, $CF_3$, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}S$- and $R^{15}R^{16}N$- when $R^3$ is one of H, HO, $R^{13}O$-, halogen, C1-C3-alkyl, $CF_3$, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}S$-, and $R^{15}R^{16}N$-; or

$R^1$ and $R^2$, or $R^2$ and $R^3$, or $R^3$ and $R^4$ taken together can be

$-SCH_2S$-,

$-SCH_2O$-,



MAR. 20. 2003 2:02PM HOLLAND & KNIGHT NO. 3533 P. 29

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



a3

.. $-OCH_2S-$,

$-SCH_2CH_2S-$,

$-SCH_2CH_2O-$, or

$-OCH_2CH_2S-$; or

one of four substituents of $R^1$, $R^2$, $R^3$ and $R^4$ must be C1-C3-alkoxy or C1-C3-alkylthio group;

$R^5$, $R^6$, and $R^7$ are independently

H,

C1-C6-alkyl,

C3-C6-alkenyl,

C3-C6-cycloalkyl, or

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen[ (F, Cl, Br)], $R^{13}O-$, $CF_3-$, $R^{14}O_2S-$, $R^{14}OS-$, $R^{14}CO$, $R^{14}CO_2-$, $R^{14}O_2C-$, $R^{14}CONH-$, $R^{14}NHCO$; or

$R^5$ and $R^6$ taken together can be C3-C6-cycloalkyl;

$R^{13}$ is C1-C3-alkyl;

$R^{14}$ is H or C1-C3-alkyl;

$R^{15}$ and $R^{16}$ are independently

H,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10-alkenyl, or



MAR. 20. 2003 2:02PM HOLLAND & KNIGHT NO. 3533 P. 30

Received from < > at 3/20/03 1:57:42 PM [Eastern Standard Time]



C3-C6-cycloalkyl; or

$R^{15}$ and $R^{16}$ taken together can be C3-C6-cycloalkyl;

[$R^{17}$ is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl;]

$a^3$

$R^{18}$ and $R^{19}$ are independently

H,

Halogen[ (F, Cl, Br)],

C1-C3-alkyl,

$R^{14}O$-,

$CF_3$-, or

$R^{14}CO_2$-;

$R^{20}$ and $R^{21}$ are independently

H,

$R^{15}R^{16}N$-,

$R^{15}HNC(NH)$-, or

$R^{14}CONH$-;

and pharmaceutically acceptable salts thereof;

wherein $R^{20}$ and $R^{21}$ cannot both be H,

in combination with a pharmaceutically acceptable carrier.

26. (amended) The method of claim 25 wherein, in the compound of Formula II, one of four substituents of $R^1$, $R^2$, $R^3$ and $R^4$ must be C1-C3-alkylthio or C1-C3-alkoxy group, the other substituents are independently H, $R^{13}O$-, $R^{13}S$-, halogen [(F, Cl, Br)], or C1-C3-alkyl; $R^2$ and $R^3$ taken together can be $-SCH_2S$-, $-SCH_2O$-, or $-OCH_2S$-;





MAR. 20. 2003 2:02PM HOLLAND & KNIGHT NO. 3533 P. 31